Clinical Trial Update: A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） [EARLY_Phase 1]

View source ↗

Summary

An early-phase study update describing a clinical trial evaluating LVIVO-TaVec400 for relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LVIVO-TaVec400

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma (MM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING